ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

311
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
13 Jan 2025 10:38

Insignia Financial (IFL AU): Bain Calls CC Capital's $4.30/Share NBIO

Both Offers are non-binding. IFL may hold out for more, but they should engage here. However, I'm still not confident Tanarra is willing to kick...

Logo
405 Views
Share
13 Jan 2025 06:15

Smart Share Global (EM US)'s MBO NBIO

Should a defintive agreement be inked, this is done. The risk to the trade, as with many US-listed China plays, is one of timing. Trading at a...

Logo
374 Views
Share
bullishESR Group
13 Jan 2025 01:34

Merger Arb Mondays (13 Jan) - ESR, Henlius, Goldlion, Canvest, 7&I, Fujitsu General, Pressance

This week, the highest gross spreads are Smart Share (26.3%), Pressance (22.1%), Seven & I (15.2%), Get Nice Financial (9.9%), ESR (8.3%), Goldlion...

Logo
674 Views
Share
12 Jan 2025 06:45

Last Week in Event SPACE: Seven & I, PA Gooddoctor, Fuji Soft, WH Group

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

Logo
486 Views
Share
12 Jan 2025 06:30

(Mostly) Asia-Pac M&A: Insignia Financial, Arcadium, CPMC, GAPack, Haitong Sec., Shinko Electric

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
487 Views
Share
x